Two Therapies, One Approved, Prevent Dementia-related Brain Damage in Mice

Two Therapies, One Approved, Prevent Dementia-related Brain Damage in Mice
Two therapies — one approved and the other already in clinical testing — were seen in a study in mice to work to reduce brain shrinkage and prevent brain cell death. The therapies block a cellular pathway known to be responsible for neurodegeneration and brain cell death in mice. One of the drugs, trazodone hydrochloride, or Desyrel,

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.


  1. At the risk of sounding pessimistic and skeptical, if I recall well all of the failed AD vaccines and monoclonal antibodies did quite well in preventing or improving this disease in transgenic mouse models; apparently the main reason why the FDA allowed them to proceed to the clinical stage. Evidently, these animal models are not as good indicators as we would like to believe.

    • Dr. J says:

      Precisely. Decades of animal research with 99% failure rate and the approval of just five crummy drugs (one so bad it was withdrawn…tacrine) by a desperate FDA. We must move to human-relevant research and escape the animal experimentation trap…or we will never catch up to AD.

  2. Leo Marcoux says:

    I am currently enrolled in the aducanumab clinical trial and would consider becoming a candidate for a similar trial of trazodone chloride or DBM if such a trial became available.


    • Dr. J says:

      Good luck to you. Aducanumab is thought to be a “supercharged solanezumab,” a more powerful A-beta antibody. The odds are long, but we can hope.

Leave a Comment

Your email address will not be published. Required fields are marked *